Can-Fite's Piclidenoson Cuts Kidney Disease Marker By Up To 80% In Preclinical Study

India, Nov. 12 -- Thursday, Can-Fite BioPharma Ltd. (CANF) announced published preclinical research demonstrating that its oral drug candidate piclidenoson corrects cellular abnormalities and reduces a kidney disease marker by 48% to 80% in models of Lowe syndrome.

Lowe syndrome is a rare genetic disorder affecting the eyes, brain, and kidneys causing impaired protein reabsorption, urinary protein loss, and progressive kidney disease for which no curative therapy currently exists.

Piclidenoson (IB-MECA) is an orally bioavailable, first-in-class A3 adenosine receptor agonist (A3AR) small molecule.

Led by researchers at the Telethon Institute of Genetics and Medicine (TIGEM) and the University of Naples Federico II, the study screened 1,28...